Safety, Efficacy Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.

Inclusion Criteria:

1. Hemophilia A.

2. FVIII:C <1%. 3）12 and 65 years old.

4）Has received FVIII treatment and the treatment exposure days ≥100. 5）Has bleedingtreatment records of at least 3 months before randomization. 6）FVIII inhibitor assayresults is negative. 7） Subjects should agree to use an adequate method of contraceptionduring the study.

8）Understood and Signed an informed consent form.

Exclusion Criteria:

1. Has a history or family history of blood coagulation factor VIII inhibitor.

2. Has other coagulation dysfunction diseases in addition to hemophilia A.

3. HIV positive.

4. Plan to receive surgery during the trial.

5. Has used immunomodulator within one weeks before the first dose，and less than 7half-life periods.

6. Known to be allergic to experimental drugs or any excipients.

7. Severe anemia and need blood transfusion.

8. Serious liver or kidney damage.

9. Serious heart disease.

10. Uncontrollable hypertension.

11. Has participated in other clinical studies within one month before the first dose.

12. The researchers believe that it is not suitable for participants.